| Bryan V Anderson, PA | |
|
1215 Lee St, Charlottesville, VA 22908-0001 | |
| (434) 924-2283 | |
| (434) 982-0019 |
| Full Name | Bryan V Anderson |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 9 Years |
| Location | 1215 Lee St, Charlottesville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023410248 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LC0200X | Anesthesiology - Critical Care Medicine | 0110005129 (Virginia) | Secondary |
| 363A00000X | Physician Assistant | 0110005129 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Virginia Medical Center | Charlottesville, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Virginia Physicians Group | 4880590728 | 1397 |
News Archive
Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."
For many women who thought they had beaten breast cancer, the news that it has roared back years later comes as an especially cruel diagnosis with no clear answers for why or how it recurs.
Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.
A new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to injectable MS medications and treatment persistence than patients who receive injectable MS medications through a community pharmacy.
Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bryan V Anderson, PA Po Box 9007, Charlottesville, VA 22906-9007 Ph: () - | Bryan V Anderson, PA 1215 Lee St, Charlottesville, VA 22908-0001 Ph: (434) 924-2283 |
News Archive
Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."
For many women who thought they had beaten breast cancer, the news that it has roared back years later comes as an especially cruel diagnosis with no clear answers for why or how it recurs.
Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.
A new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to injectable MS medications and treatment persistence than patients who receive injectable MS medications through a community pharmacy.
Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data.
› Verified 4 days ago